Tonix Pharmaceuticals Holding Corp: Regulation Fd Disclosure, On April 9, 2025, The Company Announced A Collaborative Research Agreement Under Which The Company And Makana Will Study Tnx1500 In Combination With Makana’s Humancompatible Organs And Cells For The Treatment Of Organ Failure. The Preclinical Research And Development Collaboration Has The Potential To Span Multiple Makana Programs Including Kidney, Heart And Islet Cell Transplant. The Goal Of The Preclinical Studies Is To Support The Submission Of An Investigational New Drug Application To The U.s. Food And Drug Administration To Support Compassionate Use For Patients Undergoing Xenotransplantation, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Tonix Pharmaceuticals Holding Corp.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***